Patent Term Management Toolkit: Adjustment, Extension, and Double Patenting

By Casey Scott McKay · 2024-12-15

Patent term looks like arithmetic and behaves like strategy, and the differences between two patents in the same family can be years. This toolkit sets out the twenty-year baseline, how patent term adjustment accrues through A, B, and C delay and how applicant delay reduces it, and how patent term extension under Section 156 restores time lost to regulatory review. It then works obviousness-type double patenting - the doctrine that can take back what adjustment awarded - through In re Cellect, Allergan v. MSN, and Gilead v. Natco, and sets out the terminal disclaimer decision and the Section 121 safe harbour. It closes with family expiry mapping, maintenance fee management, and the diligence questions that reveal what a portfolio's term actually is.

IP and Technology > Patent Counseling Transactions | Toolkit | Published 15 December 2024 - Updated 4 May 2025 | Casey Scott McKay - marksy.us

Summary. Patent term looks like arithmetic and behaves like strategy, and the differences between two patents in the same family can be years. This toolkit sets out the twenty-year baseline, how patent term adjustment accrues through A, B, and C delay and how applicant delay reduces it, and how patent term extension under Section 156 restores time lost to regulatory review. It then works obviousness-type double patenting — the doctrine that can take back what adjustment awarded — through In re Cellect, Allergan v. MSN, and Gilead v. Natco, and sets out the terminal disclaimer decision and the Section 121 safe harbour. It closes with family expiry mapping, maintenance fee management, and the diligence questions that reveal what a portfolio's term actually is.

Keywords: patent term · twenty year term · patent term adjustment · A delay B delay C delay · applicant delay reduction · PTA calculation · patent term extension · section 156 · regulatory review period · obviousness type double patenting · terminal disclaimer · In re Cellect · Allergan v MSN · Gilead v Natco · safe harbor section 121 · maintenance fees · family expiry mapping · Novartis v Ezra · portfolio term strategy

Start Here

Two patents in the same family. Same priority date, same specification, claims that differ in scope.

One expires in 2039. The other expires in 2042.

The difference is patent term adjustment — one prosecution took longer through no fault of the applicant, and the statute compensated for it. Three years of exclusivity on a product that may generate substantial revenue in those years.

Then a rejection arrives on a third family member, for obviousness-type double patenting over the second. The reflexive answer is a terminal disclaimer, and filing one would cut the family back to 2039 across the board — surrendering the three years the adjustment awarded, on a form that takes ten minutes to prepare.

This toolkit answers three questions.

How is term actually calculated? Twenty years from the earliest non-provisional priority, plus adjustment, plus any extension, minus disclaimers.
What can take it back? Obviousness-type double patenting, applied against the adjusted expiry.
What decisions are available? Traversal, restructuring, the safe harbour, and — last — the disclaimer.

If you read only one thing, read The Clock You Did Not Know You Were Running. It works the arithmetic and the interactions in the order they arise.

The Baseline Term

The rule. 35 U.S.C. § 154 provides a term beginning on the date the patent issues and ending twenty years from the filing date of the earliest US non-provisional application to which priority is claimed.

Provisionals do not count. A provisional under 35 U.S.C. § 111 provides a priority date without starting the term clock, which is the principal reason to use one.

Foreign priority does not count either. 35 U.S.C. § 119 priority does not shorten term.

Continuations do. A continuation claims priority to its parent, and the term runs from the parent's filing date. A continuation filed in year eight of a family has twelve years of term, not twenty.

Which is the central strategic fact about families. Every continuation shortens the effective exclusivity of what it claims, and a family strategy that files continuations indefinitely is producing shorter and shorter patents.

Design patents differ. 35 U.S.C. § 173 gives fifteen years from grant, with no adjustment and no maintenance fees.

Maintenance fees. 35 U.S.C. § 41 requires payments at three and a half, seven and a half, and eleven and a half years from grant. Non-payment causes expiry, with reinstatement available on a showing of unintentional delay for a defined period.

Patent Term Adjustment

The purpose. To compensate an applicant for Office delay that consumed term the applicant did not cause.

A delay. Failure to meet prescribed examination timeframes — issuing a first action within fourteen months, responding to a reply within four months, acting on an appeal decision within four months, and issuing within four months of the issue fee.

B delay. Failure to issue the patent within three years of the actual filing date, excluding time consumed by requests for continued examination, interferences, secrecy orders, and appellate review.

C delay. Delays due to interferences, secrecy orders, and successful appellate review.

No double counting. Overlapping periods are counted once.

Applicant delay reduces it. 35 U.S.C. § 154(b)(2)(C) reduces adjustment by the period during which the applicant failed to engage in reasonable efforts to conclude prosecution, defined in the regulations at 37 C.F.R. § 1.704.

The reductions that catch people. Responses filed more than three months after a communication, even within an extended period. Supplemental papers filed after a reply. Amendments after allowance. Requests for continued examination in some circumstances. Preliminary amendments filed late.

Supernus Pharmaceuticals v. Iancu limits reductions to periods during which the applicant could have taken action, holding that a reduction cannot exceed the time in which the applicant failed to undertake reasonable efforts.

Novartis AG v. Lee addresses the treatment of time after allowance and the exclusion of continued examination time from B delay.

The calculation. The Office computes it and states it on the patent. 37 C.F.R. § 1.705 provides for a request for reconsideration, with a short deadline after issue, followed by civil action.

Check it. Office calculations are frequently wrong, and the deadline to challenge is short. For a patent that matters, verify the adjustment against the file within the reconsideration window.

Practice consequence. Respond promptly — within three months — even when extensions are available. Every month of extension is a month of adjustment lost, and on a slow-prosecuting application that arithmetic is substantial.

Patent Term Extension

A separate regime, for products subject to regulatory review.

The statute. 35 U.S.C. § 156 permits extension of the term of a patent claiming a product, a method of using a product, or a method of manufacturing a product, where the product was subject to a regulatory review period before commercial marketing.

Eligibility. The patent must not have expired; the term must not previously have been extended; the application must be submitted within sixty days of approval; the product must have been subject to a regulatory review period; and the approval must be the first permitted commercial marketing of the product.

The calculation. Half the testing phase plus all of the approval phase, reduced for periods where the applicant did not act with due diligence, capped at five years, and further capped so that the remaining term after approval does not exceed fourteen years.

One patent per product. The applicant elects which patent to extend, and that election is consequential and irrevocable.

Interim extensions are available where the review period extends beyond the patent's expiry.

Regulations. 37 C.F.R. § 1.710 and following govern the application, which is filed with the Office and reviewed with the regulatory agency's input.

Merck & Co. v. Hi-Tech Pharmacal holds that extension applies to a term that has been shortened by a terminal disclaimer — the extension runs from the disclaimed expiry.

Novartis AG v. Ezra Ventures holds that obviousness-type double patenting does not invalidate a patent whose term was extended under 35 U.S.C. § 156, distinguishing extension from adjustment.

Which is a significant distinction. Extension is protected from the double patenting doctrine in a way adjustment, after In re Cellect, is not.

Practical consequence for life sciences. The election of which patent to extend should be made with the double patenting map in hand, because the interaction determines the family's effective exclusivity. See Life Sciences Patent Toolkit.

Obviousness-Type Double Patenting

The judge-made doctrine that can take back what adjustment awarded.

The purpose. To prevent extension of the patent monopoly through patents claiming patentably indistinct inventions, and to prevent harassment by multiple assignees.

The test. Whether the claims of the later patent are patentably indistinct from those of the earlier — an obviousness-like analysis using the reference patent's claims as the starting point, with the reference specification available only in limited ways.

It is not statutory. Unlike double patenting under 35 U.S.C. § 101, which prohibits two patents on the same invention, obviousness-type double patenting is judicially created and is cured by a terminal disclaimer.

Gilead Sciences v. Natco Pharma holds that a later-issued but earlier-expiring patent can serve as a double patenting reference against an earlier-issued but later-expiring patent. Issue order does not control; expiry order does.

In re Cellect holds that the analysis is conducted against the expiration date as adjusted by patent term adjustment under 35 U.S.C. § 154. A patent that earned substantial adjustment can therefore be invalidated for double patenting over a family member that expires earlier — or cut back by a disclaimer to that earlier date.

Allergan v. MSN Laboratories materially narrows that exposure, holding that a first-filed, first-issued patent in a family cannot be invalidated for obviousness-type double patenting by a later-issued family member claiming a patentably indistinct invention.

Novartis AG v. Ezra Ventures distinguishes extension: a patent whose term was extended under 35 U.S.C. § 156 is not invalidated for double patenting on that basis.

Which produces a coherent, if intricate, picture. Extension is protected. Adjustment is not, except that the first-filed, first-issued patent has its own protection. The exposure lives in later-issued family members carrying adjustment.

The safe harbour. 35 U.S.C. § 121 provides that a patent issuing on a divisional filed as a result of a restriction requirement is not to be used as a double patenting reference against the other. It is narrow: it protects divisionals, requires consonance with the restriction, and can be lost through amendments that cross the restriction lines.

Common ownership matters. The doctrine's harassment rationale applies where patents are separately owned, and the terminal disclaimer's common ownership condition under 37 C.F.R. § 1.321 reflects it.

The Terminal Disclaimer Decision

What it costs. Term, sometimes years of it. And a common ownership condition that binds every future transaction involving the family.

The reflexive filing is the error. A disclaimer takes ten minutes to prepare and can surrender three years of exclusivity on a product. The decision deserves an hour of analysis.

Step one — calculate what is being surrendered. The current patent's expiry with adjustment, against the reference patent's expiry. The difference is the cost.

Step two — consider traversal. Are the claims genuinely patentably indistinct? A double patenting rejection is a rejection, and it can be argued. Where the claims differ in a way that would not have been obvious, say so.

Step three — consider amendment. Narrowing or restructuring the claims to create patentable distinctness preserves the term.

Step four — check the safe harbour. If the application is a divisional filed in response to a restriction requirement, 35 U.S.C. § 121 may bar the rejection entirely. Check whether consonance has been maintained.

Step five — check Allergan v. MSN Laboratories. If the patent under rejection is the first-filed, first-issued member, the later member may not serve as a reference.

Step six — check whether extension is contemplated. Novartis AG v. Ezra Ventures protects extended term, and Merck & Co. v. Hi-Tech Pharmacal applies extension after a disclaimer — so the sequencing of disclaimer and extension election matters.

Step seven — consider abandoning the application. Where the claims add little and a disclaimer would cut back a valuable family member, letting the application go may be the better commercial answer.

Step eight — if a disclaimer is filed, scope it. Disclaim against the specific reference patent, and understand which family members become tied together by common ownership.

Record the analysis. A one-page note per disclaimer, showing what was surrendered and why. In diligence, that note is the difference between a considered decision and an unexplained loss of term.

Family Expiry Mapping

The artefact that makes all of this manageable.

One row per patent and application in the family. Columns: earliest non-provisional priority date, filing date, issue date, twenty-year base expiry, adjustment awarded, adjustment verified, extension applied and granted, terminal disclaimers filed and against which reference, actual expiry, next maintenance fee date, and claims summary.

Sort by actual expiry. That ordering reveals the double patenting exposure immediately: a later-expiring member with adjustment, sitting above an earlier-expiring family member with patentably indistinct claims, is the In re Cellect fact pattern.

Flag the first-filed, first-issued member. Allergan v. MSN Laboratories gives it protection the others lack, and knowing which patent that is changes the analysis.

Flag the safe-harbour divisionals. Applications filed in response to a restriction requirement under 35 U.S.C. § 121, with a note on whether consonance was maintained.

Flag the extension election. For life sciences families, which patent was or will be extended under 35 U.S.C. § 156, because only one may be.

Maintain it at every filing and every issue. A map built once and left is worse than none, because it will be relied on.

Use it in three places. Prosecution, when a double patenting rejection arrives. Portfolio review, when deciding what to maintain. And diligence, where it answers in one page what would otherwise take weeks.

Extend it to foreign counterparts. Terms differ, supplementary protection certificates operate differently, and a family's global exclusivity picture is not visible from the US patents alone.

Prosecution Behaviours That Determine Term

Adjustment is earned and lost through ordinary prosecution decisions, most of which are made without reference to term.

Respond within three months. Every month of extension under 37 C.F.R. § 1.704 reduces adjustment. On an application that takes five years, taking three-month extensions routinely can consume most of the adjustment earned.

Avoid supplemental papers after a reply. They reduce adjustment.

Avoid amendments after allowance unless necessary; they reduce adjustment.

Consider whether a request for continued examination is necessary. Time after an RCE is excluded from B delay, which means an RCE effectively stops the three-year clock.

File preliminary amendments promptly, because late ones reduce adjustment.

Consider appeal versus continued examination. Successful appellate review generates C delay; continued examination does not.

Interview early. An interview that resolves a rejection avoids a cycle, which shortens prosecution and preserves term in absolute terms even where it reduces adjustment.

Watch the issue fee. Adjustment accrues for Office delay in issuing after payment, and applicant delay after allowance reduces it.

Verify the calculation within the reconsideration window. 37 C.F.R. § 1.705 sets a short deadline, and Office calculations are frequently wrong. For a patent that matters, this check is worth doing every time.

Decide continuation strategy with term in mind. A continuation filed late in a family has short term, and filing one to pursue marginal claims may not be worth the cost of maintaining it.

Maintenance and Portfolio Pruning

Term is only worth what the company pays to keep.

The schedule. 35 U.S.C. § 41 requires maintenance fees at three and a half, seven and a half, and eleven and a half years from grant, with a six-month grace period and a surcharge.

Expiry for non-payment is automatic, and reinstatement requires a petition showing the delay was unintentional, available for a defined period.

Each payment is a decision. The seven-and-a-half-year payment is where most pruning should happen, because by then the commercial value of the claims is knowable.

Build the review. Six months before each due date, a review asking: does this patent cover a current or planned product; does it cover a competitor's product; is it licensed; is it part of a family whose other members carry the coverage; and would a competitor pay to keep it alive.

Consider selling rather than abandoning. A patent a company will not maintain may have value to someone else, and an abandoned patent has none.

Consider the defensive publication effect. An expired patent remains prior art, so abandonment does not surrender the defensive value of the disclosure.

Watch the family effect. Abandoning the first-filed, first-issued member removes the Allergan v. MSN Laboratories protection it provided and can change the double patenting posture of the rest.

Watch the terminal disclaimer effect. A patent tied to a reference patent by disclaimer is enforceable only while commonly owned, which means selling one and keeping the other creates unenforceability.

Record the reasoning. A one-line note per abandonment decision, so that a later question about why a patent lapsed has an answer.

And check the foreign counterparts separately. Annuity schedules differ, and a portfolio maintained in the United States and lapsed abroad is a common and expensive misalignment.

Worked Example: The Family With Three Expiries

A family: a parent filed in 2018, a continuation filed in 2020, and a divisional filed in 2021 in response to a restriction requirement.

The parent. Base expiry 2038. Prosecution was slow through Office delay; adjustment of 480 days. Actual expiry mid-2039. First filed and first issued.

The continuation. Base expiry 2038, same priority. Prosecution was fast, and applicant delay under 37 C.F.R. § 1.704 — three-month extensions taken twice — reduced adjustment to 60 days. Actual expiry late 2038.

The divisional. Base expiry 2038. Adjustment of 700 days from a long appeal, generating C delay. Actual expiry late 2039 — the longest in the family.

The rejection. The divisional receives an obviousness-type double patenting rejection over the continuation, which expires a year earlier. Under Gilead Sciences v. Natco Pharma and In re Cellect, the rejection is available notwithstanding issue order.

The analysis. First, the safe harbour: the divisional was filed in response to a restriction requirement, so 35 U.S.C. § 121 may bar the rejection — provided consonance with the restriction was maintained, which the file confirms. The rejection is traversed on that basis and withdrawn.

Had the safe harbour not applied. The options were traversal on patentable distinctness, amendment to create distinctness, or a disclaimer surrendering roughly a year of the divisional's term.

The parent's position. Protected from double patenting invalidation by the later members under Allergan v. MSN Laboratories, so its 480 days of adjustment are secure.

The lesson. Three patents, three different expiries, one avoided disclaimer worth a year of exclusivity, and the analysis took an hour with a family map already in hand. Without the map, the disclaimer would have been filed on the day the rejection arrived.

The Life Sciences Overlay

Term management matters more here than anywhere, because a single product's exclusivity determines a company's value.

Extension election. 35 U.S.C. § 156 permits one patent per product, and the election is consequential. The candidate patents typically include a compound patent, a formulation patent, and a method-of-use patent, with different scopes and different base expiries.

Elect the patent with the best combination of scope and resulting expiry, not simply the one that expires latest. A narrow patent extended to a late date protects less than a broad patent extended to an earlier one.

Novartis AG v. Ezra Ventures protects extended term from double patenting invalidation, which makes extension strategically safer than adjustment.

Merck & Co. v. Hi-Tech Pharmacal applies extension to a term already shortened by a terminal disclaimer, so the two operate in sequence rather than cancelling.

Regulatory exclusivities run alongside. New chemical entity exclusivity, orphan drug exclusivity, paediatric exclusivity, and biologic exclusivity under the relevant statutes operate independently of patent term and can extend effective protection past patent expiry, or fall short of it.

Listing decisions. Which patents are listed with the regulatory agency determines which are subject to the certification and notice regime, and that decision interacts with the extension election. See Life Sciences Patent Toolkit.

Paediatric extension adds to both patent term and regulatory exclusivity in defined circumstances, and the arithmetic should be run before the extension election is fixed.

Foreign supplementary protection certificates operate on different rules with different maximum durations, and the global exclusivity map is what the business actually needs.

Build the map early. For a product entering clinical development, the exclusivity map should exist years before approval, because the filing and continuation decisions that determine it are being made then.

Diligence Questions

What is each patent's actual expiry? Not the base expiry. Base plus adjustment plus extension minus disclaimers.

Has the adjustment been verified? Office calculations are frequently wrong, and the 37 C.F.R. § 1.705 window is short. A portfolio where nobody checked may hold more or less term than the face of the patents suggests.

Which patents carry terminal disclaimers, and against what? 37 C.F.R. § 1.321 conditions enforceability on common ownership, which constrains how the portfolio can be divided in the transaction being contemplated.

Which patents carry adjustment and have later-expiring family members? That is the In re Cellect exposure, mitigated for the first-filed, first-issued member by Allergan v. MSN Laboratories.

Which applications are safe-harbour divisionals, and was consonance maintained?

Has extension been applied for or granted, and on which patent, and was the election optimal?

What are the next maintenance fee dates, and is anyone tracking them through the transition?

What is the foreign position? Terms and annuity schedules differ, and lapses abroad are common.

Is there a family expiry map? Its absence is itself a finding, and building one is the first thing the buyer's counsel will have to do.

What is the effective exclusivity on the lead product, taking patents, extension, and regulatory exclusivities together? That single number is what the valuation depends on.

Common Mistakes

Filing a terminal disclaimer reflexively. Ten minutes of preparation surrendering years of exclusivity, without an analysis of what was given up or whether the rejection could have been traversed.

Not checking the safe harbour under 35 U.S.C. § 121 before disclaiming, when a divisional filed in response to a restriction may be immune.

Losing safe harbour consonance through amendments that cross the restriction lines, without appreciating the consequence.

Never verifying the adjustment. 37 C.F.R. § 1.705 sets a short reconsideration window, and Office calculations are frequently wrong in both directions.

Taking extensions routinely. Every month reduces adjustment under 37 C.F.R. § 1.704, and on a slow application the cumulative effect is substantial.

Filing supplemental papers after a reply, which reduces adjustment for no benefit.

Treating the twenty-year clock as running from the patent's own filing date, when 35 U.S.C. § 154 runs it from the earliest non-provisional priority.

Filing continuations indefinitely without noticing that each has less term than the last.

Making the extension election without the double patenting map, and extending a patent whose scope does not carry the product.

Assuming extension and adjustment behave alike. Novartis AG v. Ezra Ventures protects extension from double patenting; In re Cellect does not protect adjustment.

Splitting a disclaimed family in a transaction, rendering the disclaimed patents unenforceable for want of common ownership.

Abandoning the first-filed, first-issued member and losing the Allergan v. MSN Laboratories protection it supplied to the family.

Maintaining everything. A portfolio where no patent is ever pruned is a cost centre with a term column nobody reads.

Letting foreign annuities lapse while paying US maintenance fees, producing a portfolio protected in one market and abandoned in the others.

The One-Page Position

Term position — [family or portfolio], [date]. Patents: [N]; applications pending: [N]. Earliest non-provisional priority [date]; base expiry [date]. Adjustment: awarded on [N] patents, total [N] days; verified within the 37 C.F.R. § 1.705 window on [N]; [N] reconsideration requests filed, [N] granted. Extension: [applied / granted] on [patent], adding [N] days; election rationale recorded [date]. Terminal disclaimers: [N] in force, against reference patents [list]; term surrendered [N] days total; common ownership constraint documented. Double patenting exposure: [N] later-expiring members with adjustment, [N] protected as first-filed first-issued under Allergan v. MSN Laboratories, [N] protected as safe-harbour divisionals under 35 U.S.C. § 121. Actual expiries, sorted: [list]. Longest-running claim coverage on the lead product: [date]. Next maintenance fees: [dates]. Foreign counterparts: [N], next annuities [dates]. Recommended actions: [verify adjustment on X within the window / traverse rather than disclaim on Y / re-run the extension election / prune the Z sub-family at the next fee].

A Closing Note

Term is the only patent variable that is purely arithmetic and almost never calculated.

Companies model royalty rates to two decimal places and cannot say when their lead patent expires. Prosecutors take three-month extensions as a matter of habit without noticing that each one reduces the adjustment the statute was about to award. Terminal disclaimers are filed by return of post on rejections that could have been traversed.

None of this requires expertise so much as a table. Build the family expiry map, verify the adjustment while the window is open, analyse before disclaiming, and review at each maintenance fee. Four habits, and they are worth more in exclusivity than most prosecution strategy.

Questions Clients Ask

When does our patent expire? Twenty years from the earliest non-provisional priority date under 35 U.S.C. § 154, plus any adjustment, plus any extension, minus any terminal disclaimer. The face of the patent shows the adjustment but not the disclaimers.

Does the provisional shorten our term? No. That is the point of it — a priority date without starting the twenty-year clock.

Our continuation issued later. Does it last longer? No. It runs from the same earliest non-provisional priority date. Later issue means later start and the same end.

The Office gave us 400 days of adjustment. Is that right? Possibly not. Verify it against the file within the 37 C.F.R. § 1.705 window, which is short.

We got a double patenting rejection. Should we just file a disclaimer? Not without calculating what it costs. Check the safe harbour under 35 U.S.C. § 121, consider traversal, consider amendment, and check whether Allergan v. MSN Laboratories applies.

Can a later patent kill an earlier one? Gilead Sciences v. Natco Pharma says a later-issued but earlier-expiring patent can serve as a reference, and In re Cellect applies the analysis against adjusted expiries. Allergan v. MSN Laboratories protects the first-filed, first-issued member.

Can we extend more than one patent for our product? No. 35 U.S.C. § 156 permits one, and the election is irrevocable in practice.

Does a terminal disclaimer affect our extension? Merck & Co. v. Hi-Tech Pharmacal applies extension to the disclaimed term, so they operate in sequence.

We are selling part of the portfolio. Any issues? Yes, if any patents carry terminal disclaimers. 37 C.F.R. § 1.321 conditions enforceability on common ownership, so the disclaimed patent and its reference must move together.

Should we take the extension on the response? Only if you need it. Every month reduces adjustment under 37 C.F.R. § 1.704.

We missed a maintenance fee. 35 U.S.C. § 41 allows a grace period with surcharge, and reinstatement on a showing of unintentional delay for a defined period after that. Move quickly.

How do we know what our exclusivity actually is? Build the family expiry map, add extension and regulatory exclusivities where applicable, and read the bottom line. Most companies have never done it.

The Family Expiry Map Template

| # | Patent / app | Filed | Earliest non-prov priority | Issued | Base expiry | PTA days | PTA verified | PTE days | Terminal disclaimer (ref.) | Actual expiry | Next fee | Claims | |---|---|---|---|---|---|---|---|---|---|---|---|---| | 1 | 11,111,111 | 2018-03-04 | 2018-03-04 | 2021-06-15 | 2038-03-04 | 480 | Yes | — | none | 2039-06-27 | 2033-06-15 | Apparatus, broad | | 2 | 11,222,222 | 2020-01-20 | 2018-03-04 | 2022-09-06 | 2038-03-04 | 60 | Yes | — | none | 2038-05-03 | 2034-09-06 | Method of use | | 3 | 11,333,333 (div.) | 2021-05-11 | 2018-03-04 | 2024-02-13 | 2038-03-04 | 700 | Pending | — | none — safe harbour | 2040-02-01 | 2027-08-13 | Sub-assembly | | 4 | 18/999,999 | 2025-04-02 | 2018-03-04 | pending | 2038-03-04 | — | — | — | — | — | — | Narrow variant |

Sort by actual expiry to reveal the double patenting exposure at a glance.
Flag row 1 as first-filed and first-issued, carrying the Allergan v. MSN Laboratories protection.
Flag row 3 as a safe-harbour divisional under 35 U.S.C. § 121, with a note on consonance.
Populate PTA verified honestly. "Pending" and "No" are answers; a blank is a gap.
Add a foreign sheet with counterpart terms, supplementary protection certificates, and annuity dates.
Review at every filing, every issue, and every maintenance fee.

What This Costs

Building the family expiry map. A day for an established family, less thereafter. It is a spreadsheet, not a project.

Verifying adjustment. An hour per patent, within the 37 C.F.R. § 1.705 window. For a portfolio, sample the ones that matter and verify all of them for the lead family.

A reconsideration request. Modest, and occasionally worth months of term.

Analysing a double patenting rejection properly. An hour, against a disclaimer that takes ten minutes and can cost years.

Traversing rather than disclaiming. One additional response cycle, which itself costs a little term through delay — and preserves considerably more.

The extension application. Substantial work, and it must be filed within sixty days of approval under 35 U.S.C. § 156. There is no relief for missing it.

Maintenance fees. The largest recurring cost in most portfolios, and the one most amenable to disciplined pruning.

Against all of that: the value of a year of exclusivity on a commercially significant product, which for many companies exceeds the entire annual patent budget.

The arithmetic on this toolkit's subject is unusually favourable, which is why the habits it describes are worth building even in a portfolio that is otherwise managed lightly.

Building the Function

One owner. Someone accountable for the family expiry maps, usually in the docketing or portfolio management function with a line to prosecution counsel.

A verification standard. Adjustment verified within the reconsideration window for every patent in a designated priority set, and sampled elsewhere.

A rejection protocol. Every obviousness-type double patenting rejection routed to a defined analysis — safe harbour, traversal, amendment, Allergan v. MSN Laboratories status, cost of disclaimer — before any disclaimer is filed.

A prosecution instruction. Respond within three months where possible; avoid supplemental papers after a reply; escalate before filing a request for continued examination on a slow application.

A maintenance review. Six months before each fee, against the criteria above, with a recorded decision.

A transaction gate. No sale, spin-out, or divestiture of part of a family without checking terminal disclaimer common-ownership constraints.

An annual portfolio report. Actual expiries sorted, exposures flagged, fees forecast, and the effective exclusivity on lead products stated in one line.

Five Rules

Term runs from the earliest non-provisional priority date, not from the patent's own filing date, and every continuation inherits that clock.
Adjustment is earned by Office delay and lost by yours. Respond within three months; verify the calculation within the reconsideration window.
Extension is protected from double patenting; adjustment is not. Novartis AG v. Ezra Ventures against In re Cellect is the distinction that shapes life sciences strategy.
Never disclaim without calculating the cost and checking the safe harbour under 35 U.S.C. § 121 and the Allergan v. MSN Laboratories position.
Keep the map. A family expiry map, sorted by actual expiry, answers in one page what would otherwise take a diligence team a week — and it is what tells the business when its exclusivity actually ends.

Everything else in this toolkit is elaboration on those five rules, and a portfolio managed by them will hold measurably more exclusivity than one managed without them — at essentially no incremental cost.

A Suggested Reading Path

For the arithmetic:

For the prosecution behaviours that produce it:

For the life sciences interaction:

Primary Authorities

| Authority | Proposition | |---|---| | 35 U.S.C. § 154 | Term; patent term adjustment | | 35 U.S.C. § 156 | Patent term extension | | 35 U.S.C. § 111 | Applications; provisionals | | 35 U.S.C. § 119 | Foreign and provisional priority | | 35 U.S.C. § 120 | Continuation priority | | 35 U.S.C. § 121 | Divisionals; safe harbour | | 35 U.S.C. § 173 | Design patent term | | 35 U.S.C. § 253 | Disclaimers | | 35 U.S.C. § 41 | Maintenance fees | | 37 C.F.R. § 1.702 | Grounds for adjustment | | 37 C.F.R. § 1.703 | Period of adjustment | | 37 C.F.R. § 1.704 | Reduction for applicant delay | | 37 C.F.R. § 1.705 | Reconsideration of adjustment | | 37 C.F.R. § 1.710 | Extension eligibility | | 37 C.F.R. § 1.321 | Terminal disclaimers | | In re Cellect | ODP against PTA-adjusted expiry | | Allergan v. MSN Laboratories | First-filed first-issued patent | | Gilead Sciences v. Natco Pharma | Later-issued earlier-expiring reference | | Novartis AG v. Ezra Ventures | PTE not cut back by ODP | | Merck & Co. v. Hi-Tech Pharmacal | PTE applied after terminal disclaimer | | Supernus Pharmaceuticals v. Iancu | Limits on applicant delay reduction | | Novartis AG v. Lee | B delay and continued examination | | 21 U.S.C. § 355 | Drug approval; regulatory review period |

Forms and Templates

The Portfolio Inventory Template is the operative document for term management, and the columns that matter are rarely the ones companies populate: earliest non-provisional priority date, twenty-year base expiry, adjustment awarded, adjustment verified or not, extension applied for and granted, terminal disclaimers filed and against which reference patent, resulting actual expiry, and the next maintenance fee date. A portfolio inventory without an actual-expiry column overstates what the company holds, sometimes by years in both directions. The Office Action Response Template matters more than it appears to, because the response habits it encodes — filing within three months rather than taking extensions, avoiding supplemental papers after a reply — are what determine whether adjustment accrues or is reduced under 37 C.F.R. § 1.704. The Assignment Agreement Template is relevant because terminal disclaimers under 37 C.F.R. § 1.321 condition enforceability on continued common ownership, so assignment discipline within a family is what keeps disclaimed patents enforceable.

Related Toolkits and Checklists

The Patent Prosecution Toolkit covers the prosecution decisions that generate or destroy adjustment. The Patent Post-Issuance Correction Toolkit covers terminal disclaimers alongside the other correction mechanisms, and the Patent Term Checklist runs the verification and mapping steps in order. For products subject to regulatory review, the Life Sciences Patent Toolkit covers extension elections in the context of the exclusivity regime they interact with. And the IP Due Diligence Toolkit covers the term verification a buyer should run, which is one of the few diligence exercises that reliably changes a valuation.